ARPA-H is seeking proposals from experts in surgery, imaging and AI, including academic and scientific research institutions ...

As the FDA's Commissioner's National Priority Voucher (CNPV) program has picked up steam, with 15 companies now having ...

Most AI drug development is fueled by foundation models in biology—models that are trained on vast biological data sets and ...

The FDA has delayed a decision on Ascendis Pharma’s dwarfism drug candidate TransCon CNP, pushing back the deadline by three ...

Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal ...

The Federal Trade Commission (FTC) has begun outlining its case against Edwards Lifesciences' proposed purchase of heart ...

Abbott has launched an effort to replace some of its FreeStyle Libre 3 continuous glucose monitors—following reports of ...

Merck & Co. is putting down $30 million upfront to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma (GBM).

AbbVie is opening submissions for an award that will provide one Canadian biotech with free access to lab space and executive ...

GE HealthCare is raising the curtain on its spearhead into the field of photon-counting CT, the Photonova Spectra, with an ...

French vaccine developer Valneva is closing down a site that houses both operational and R&D work, impacting 30 employee roles. | French vaccine maker Valneva is closing down a site that houses both ...

A drug safety group has delivered a positive analysis for a Sarepta Therapeutics-licensed RNA medicine, with the same study ...